

Christian Berthou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11984732/publications.pdf>

Version: 2024-02-01

119
papers

4,480
citations

159358

30
h-index

118652

62
g-index

119
all docs

119
docs citations

119
times ranked

5105
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of 200 mg/m ² melphalan and 8 Gy total body irradiation plus 140 mg/m ² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. <i>Blood</i> , 2002, 99, 731-735.	0.6	531
2	Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 363, 2511-2521.	13.9	362
3	Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. <i>Blood</i> , 2006, 107, 3474-3480.	0.6	344
4	Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. <i>Blood</i> , 2004, 104, 3028-3037.	0.6	222
5	BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB-TREATED patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 1464-1477.	6.7	193
6	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009, 113, 995-1001.	0.6	144
7	Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2827-2832.	0.8	129
8	A Cluster of Pneumocystis Infections Among Renal Transplant Recipients: Molecular Evidence of Colonized Patients as Potential Infectious Sources of <i>Pneumocystis jirovecii</i> . <i>Clinical Infectious Diseases</i> , 2012, 54, e62-e71.	2.9	107
9	Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. <i>Blood</i> , 2006, 107, 397-403.	0.6	94
10	<i>ABL1</i> fusion genes in hematological malignancies: a review. <i>European Journal of Haematology</i> , 2011, 86, 361-371.	1.1	84
11	Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. <i>European Journal of Cancer</i> , 2014, 50, 3206-3211.	1.3	79
12	Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2007, 85, 281-287.	1.4	71
13	Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the intergroupe francophone du myélome (IFM). <i>The Hematology Journal</i> , 2002, 3, 185-192.	2.0	71
14	Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. <i>Blood</i> , 2011, 118, 679-685.	0.6	68
15	CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation. <i>Journal of Immunology</i> , 2011, 186, 4835-4844.	0.4	65
16	PEG-IFN- α 2a therapy in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2009, 146, 223-225.	1.2	64
17	Granzyme B and perforin can be used as predictive markers of acute rejection in heart transplantation. <i>European Journal of Immunology</i> , 1994, 24, 229-233.	1.6	59
18	Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. <i>Blood</i> , 2003, 102, 4298-4305.	0.6	59

#	ARTICLE	IF	CITATIONS
19	Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. <i>Blood</i> , 2004, 104, 2675-2681.	0.6	54
20	B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients. <i>Journal of Immunology</i> , 2005, 174, 3749-3756.	0.4	50
21	Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. <i>Liver</i> , 1998, 18, 391-397.	0.1	49
22	Selection of the Alternative Exon 1 from the <i>cd5</i> Gene Down-Regulates Membrane Level of the Protein in B Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 2010-2018.	0.4	48
23	CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. <i>Cellular and Molecular Immunology</i> , 2018, 15, 158-170.	4.8	45
24	B-Cell Depletion and Repopulation in Autoimmune Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 50-55.	2.9	43
25	Impact of early molecular response in children with chronic myeloid leukemia treated in the French Clivec phase 4 study. <i>Blood</i> , 2014, 124, 2408-2410.	0.6	37
26	Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. <i>Annals of Hematology</i> , 2008, 87, 537-544.	0.8	36
27	B Lymphocytes Are Required for Development and Treatment of Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2005, 1050, 19-33.	1.8	35
28	Early versus late intensification for patients with high-risk Hodgkin lymphoma: 3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation. <i>Cancer</i> , 2008, 113, 3323-3330.	2.0	35
29	Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells. <i>Cancer Research</i> , 2008, 68, 7512-7519.	0.4	34
30	Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. , 1999, 86, 1496-1505.		33
31	Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus. <i>Immunology</i> , 2007, 122, 371-380.	2.0	33
32	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	2.2	33
33	Inhibition of NF- κ B-Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells. <i>Clinical Cancer Research</i> , 2013, 19, 2393-2405.	3.2	31
34	Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. <i>Haematologica</i> , 2007, 92, 1623-1630.	1.7	30
35	Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. <i>Journal of Immunology</i> , 2016, 196, 3199-3211.	0.4	30
36	Mass Spectrometry Analysis of the Oligomeric C1q Protein Reveals the B Chain as the Target of Trypsin Cleavage and Interaction with Fucoidan. <i>Biochemistry</i> , 2005, 44, 2602-2609.	1.2	29

#	ARTICLE	IF	CITATIONS
37	Complement System: a Neglected Pathway in Immunotherapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 58, 155-171.	2.9	29
38	A fluorescence in situ hybridization study of TEL-AML1 fusion gene in B-cell acute lymphoblastic leukemia (1984-2001). <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 143-147.	1.0	28
39	Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. <i>Cancer Genetics and Cytogenetics</i> , 2010, 200, 8-15.	1.0	27
40	Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: A study of 7 patients and review of the literature. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 44, 268-274.	0.6	27
41	AML1 amplification in a case of childhood acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2002, 137, 142-145.	1.0	26
42	Establishment of a novel human B-CLL-like xenograft model in nude mouse. <i>Leukemia Research</i> , 2005, 29, 1347-1352.	0.4	26
43	Identification of MLL partner genes in 27 patients with acute leukemia from a single cytogenetic laboratory. <i>Molecular Oncology</i> , 2011, 5, 555-563.	2.1	26
44	FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. <i>Leukemia Research</i> , 1998, 22, 303-312.	0.4	25
45	Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. <i>Blood</i> , 2004, 103, 58-66.	0.6	25
46	Interferon- γ -induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis. <i>Blood</i> , 2000, 95, 2329-2336.	0.6	23
47	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2018, 5, e82-e94.	2.2	23
48	Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. <i>Oncotarget</i> , 2018, 9, 31590-31605.	0.8	23
49	Insertion of chromosome 11 in chromosome 4 resulting in a MLL- AF4 fusion gene in a case of adult acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003, 145, 74-77.	1.0	22
50	Peripheral blood stem cell collection in elderly patients. <i>Annals of Hematology</i> , 2010, 89, 317-321.	0.8	21
51	Floridoside Extracted from the Red Alga <i>Mastocarpus stellatus</i> Is a Potent Activator of the Classical Complement Pathway. <i>Marine Drugs</i> , 2008, 6, 407-417.	2.2	21
52	Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. <i>Annals of Hematology</i> , 2012, 91, 715-721.	0.8	20
53	Decreased in vitro megakaryocyte colony formation in chronic idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 1993, 85, 803-804.	1.2	19
54	Deletion of the 5'ABL Region in Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Frequency, Origin and Prognosis. <i>Leukemia and Lymphoma</i> , 2003, 44, 1333-1338.	0.6	19

#	ARTICLE	IF	CITATIONS
55	Occupation and Lymphoid Malignancies: Results From a French Case-Control Study. <i>Journal of Occupational and Environmental Medicine</i> , 2007, 49, 1339-1350.	0.9	19
56	A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. <i>Annals of Hematology</i> , 2009, 88, 85-88.	0.8	19
57	17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. , 2019, 7, 22.		19
58	Iron, neurobioavailability and depression. <i>EJHaem</i> , 2022, 3, 263-275.	0.4	19
59	Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. <i>Molecular Cancer</i> , 2011, 10, 42.	7.9	18
60	The arachidonic acid LTB4-BLT2 pathway enhances human B-CLL aggressiveness. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2096-2105.	1.8	18
61	STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia. , 2019, 7, 111.		18
62	Exopolysaccharides Isolated from Hydrothermal Vent Bacteria Can Modulate the Complement System. <i>PLoS ONE</i> , 2014, 9, e94965.	1.1	17
63	Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. <i>Annals of Hematology</i> , 2006, 85, 244-249.	0.8	16
64	Occupational exposure to organic solvents and lymphoid neoplasms in men: results of a French case-control study. <i>Occupational and Environmental Medicine</i> , 2010, 67, 664-672.	1.3	16
65	Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome. <i>European Journal of Haematology</i> , 2012, 88, 249-259.	1.1	16
66	Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. <i>Leukemia and Lymphoma</i> , 2018, 59, 2812-2820.	0.6	16
67	Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 170, 89-92.	1.0	15
68	JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort. <i>Annals of Hematology</i> , 2017, 96, 383-386.	0.8	15
69	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1597-1609.	3.3	15
70	Long-term outcome of imatinib 400mg compared to imatinib 600mg or imatinib 400mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021, 35, 2332-2345.	3.3	15
71	Jumping translocations in multiple myeloma. <i>Cancer Genetics and Cytogenetics</i> , 2005, 161, 159-163.	1.0	14
72	Improvement of Rituximab Efficiency in Chronic Lymphocytic Leukemia by CpG-Mediated Upregulation of CD20 Expression Independently of PU.1. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 721-728.	1.8	14

#	ARTICLE	IF	CITATIONS
73	Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas. <i>Cancer</i> , 2010, 116, 4054-4062.	2.0	14
74	Circulation of <i>Pneumocystis</i> dihydropteroate synthase mutants in France. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 119-124.	0.8	14
75	Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion. <i>European Journal of Haematology</i> , 2016, 96, 229-235.	1.1	14
76	Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery. <i>Leukemia and Lymphoma</i> , 2014, 55, 74-77.	0.6	13
77	Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion. <i>Clinical Epigenetics</i> , 2017, 9, 122.	1.8	13
78	Cytogenetic Studies in T-Cell Acute Lymphoblastic Leukemia (1981-2002). <i>Leukemia and Lymphoma</i> , 2004, 45, 287-290.	0.8	12
79	Screening by fluorescence in situ hybridization for MLL status at diagnosis in 239 unselected patients with acute myeloblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2005, 161, 110-115.	1.0	12
80	Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and trisomic chromosomes, resulting in the loss of critical 5q regions. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 125-131.	1.0	12
81	Increasing of HER2 Membranar Density in Human Glioblastoma U251MG Cell Line Established in a New Nude Mice Model. <i>Journal of Neuro-Oncology</i> , 2006, 76, 249-255.	1.4	11
82	Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells. <i>Haematologica</i> , 2012, 97, 288-296.	1.7	11
83	The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. <i>Leukemia and Lymphoma</i> , 2017, 58, 2582-2587.	0.6	11
84	Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 65699-65716.	0.8	11
85	Therapeutic activity of two xanthenes in a xenograft murine model of human chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2010, 3, 49.	6.9	10
86	Pegylated interferon β 2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation. <i>Annals of Hematology</i> , 2013, 92, 407-409.	0.8	10
87	Cytokine-regulated expression and inhibitory function of Fc γ RIIB1 and -B2 receptors in human dendritic cells. <i>Journal of Leukocyte Biology</i> , 2006, 79, 59-70.	1.5	9
88	Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 328-334.	0.6	9
89	Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations. <i>Cancer Genetics and Cytogenetics</i> , 2005, 157, 169-174.	1.0	8
90	Is the <i>c-myc</i> Proto-Oncogene Involved in Chronic Lymphocytic Leukemia?. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 193-205.	1.8	8

#	ARTICLE	IF	CITATIONS
91	Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: A French case-control study. <i>International Journal of Cancer</i> , 2009, 124, 1188-1195.	2.3	8
92	Translocation (12;21) followed by insertion of chromosome 3 material in the derivative chromosome 12 in a case of childhood acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003, 142, 120-123.	1.0	7
93	Glycoprotein 170 Induces Platelet-Activating Factor Receptor Membrane Expression and Confers Tumor Cell Hypersensitivity to NK-Dependent Cell Lysis. <i>Journal of Immunology</i> , 2004, 172, 3604-3611.	0.4	7
94	Identification of a MLL-MLLT4 fusion gene resulting from a t(6;11)(q27;q23) presenting as a del(11q) in a child with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1570-1573.	0.6	7
95	Long-Term Follow-Up of Tandem High-Dose Therapy with Autologous Stem Cell Support for Adults with High-Risk Age-Adjusted International Prognostic Index Aggressive non-Hodgkin Lymphomas: A GOELAMS Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 935-940.	2.0	7
96	Pneumocystis jirovecii haplotypes at the internal transcribed spacers of the rRNA operon in French HIV-negative patients with diverse clinical presentations of Pneumocystis infections. <i>Medical Mycology</i> , 2013, 51, 851-862.	0.3	7
97	Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 321-332.	2.7	7
98	Isochromosome 5p and related anomalies: a novel recurrent chromosome abnormality in myeloid disorders. <i>Cancer Genetics and Cytogenetics</i> , 2010, 200, 134-139.	1.0	6
99	Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 303-308.	1.0	6
100	Development of a Murine model to dissect the CpG-oligonucleotide-enhancement of the killing of human B Cells by rituximab. <i>Journal of Autoimmunity</i> , 2010, 34, 136-144.	3.0	6
101	Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 115, 225-226.	1.8	6
102	Intensive Therapy before or during the Conditioning Regimen of Allogeneic Marrow Transplantation in Adult Acute Lymphoblastic Leukemia Patients: We Must Choose to Reduce Toxicity. A Groupe Ouest-Est de l'Etude des Leucémies et Autres Maladies du Sang Study. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 448-454.	2.0	5
103	Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. <i>Cancer</i> , 2008, 112, 846-855.	2.0	4
104	A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency. <i>Oncotargets and Therapy</i> , 2010, 3, 99.	1.0	4
105	Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. <i>Journal of Biomedical Science</i> , 2015, 22, 57.	2.6	4
106	Encephalitozoon hellem in a patient with CD4+ T-cell polymorphocytic leukemia: case report and genomic identification. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 245-247.	0.8	4
107	Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 23-28.	1.2	4
108	t(4;11)(q21;p15), including one complex translocation t(1;4;11)(p32;q21;p15), in adult T-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2003, 27, 965-967.	0.4	3

#	ARTICLE	IF	CITATIONS
109	A second case of secondary acute myeloblastic leukemia associated with the MLL-KIAA0284 fusion gene. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 42, 292-293.	0.6	3
110	DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag. <i>Future Science OA</i> , 2018, 4, FSO265.	0.9	3
111	Carbohydrate composition of human megakaryocyte membranes in culture: Identification using binding of seven lectins. <i>International Journal of Cell Cloning</i> , 1991, 9, 233-238.	1.6	2
112	Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only. <i>Leukemia and Lymphoma</i> , 2017, 58, 2258-2260.	0.6	2
113	Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2022, 111, 313-325.	1.5	2
114	Isolated 5p isochromosome in myelodysplastic syndrome: Report of the first case. <i>Leukemia Research</i> , 2011, 35, e193-e197.	0.4	1
115	Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients. <i>Annals of Hematology</i> , 2016, 95, 529-531.	0.8	1
116	Improved Outcome with Androgens as Maintenance Treatment in Elderly Patients with Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial. <i>Blood</i> , 2008, 112, 556-556.	0.6	1
117	Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study. <i>Blood</i> , 2013, 122, 4001-4001.	0.6	1
118	Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling. <i>Electronic Journal of Biotechnology</i> , 2012, 15, .	1.2	0
119	Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation. <i>Leukemia and Lymphoma</i> , 2013, 54, 76-82.	0.6	0